Press Releases

Date Title
Toggle Summary Aeglea BioTherapeutics Doses First Patient in Phase 1 Study of AEB1102 for Treatment of Solid Tumors
-- Top-Line Data is Expected in 2016 – Austin, Texas (October 26, 2015) - Aeglea BioTherapeutics, Inc., a biopharmaceutical company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the dosing of
Toggle Summary Aeglea BioTherapeutics Announces Promotion of Charles N. York to Chief Financial Officer
Austin, Texas (September 28, 2015) - Aeglea BioTherapeutics, Inc., a biopharmaceutical company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the promotion of Charles N.
Toggle Summary Aeglea BioTherapeutics Announces Publication of Nonclinical Data on Lead Molecule, AEB1102, in Human Molecular Genetics
Austin, Texas, (September 16, 2015) – Aeglea BioTherapeutics, Inc., a biopharmaceutical company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced publication of nonclinical data on its lead
Toggle Summary Aeglea BioTherapeutics Announces FDA Acceptance of Investigational New Drug Application for AEB1102
Austin, Texas (September 14, 2015) – Aeglea BioTherapeutics, Inc., a biopharmaceutical company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the U.S.
Toggle Summary Aeglea Biotherapeutics Appoints Sandy Mahatme and Russell Cox to Board of Directors
AUSTIN, Texas--( BUSINESS WIRE )--Aeglea Biotherapeutics, Inc., a biopharmaceutical company committed to developing enzyme based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, today announced the appointment of Sandy Mahatme and Russell Cox to
Toggle Summary Aeglea Biotherapeutics Raises $44 Million in Series B Financing
-- Financing will support development of novel treatments for inborn errors of metabolism as well as therapies targeting tumor metabolism -- AUSTIN, Texas--( BUSINESS WIRE )--Aeglea Biotherapeutics, Inc., a biopharmaceutical company developing novel treatments for inborn errors of metabolism and